Watson Wins FDA Approval For Levonorgestrel

Anonymous User | Login

Published: 24-Jun-2009

The company plans to market the product under the trade name, Next Choice

Watson has announced that its subsidiary, Watson Laboratories, has received FDA approval for its Abbreviated New Drug Application (ANDA). The approval is meant for its levonorgestrel tablets, 0.75 mg, for women seventeen years and younger. Levonorgestrel is the generic equivalent to Duramed Pharmaceuticals' PLAN B, which is indicated for the prevention of pregnancy following unprotected intercourse or contraceptive failure.

The company plans to market the product under the trade name Next Choice and launch the product shortly. Levonorgestrel is approved for prescription use only.

Watson is engaged in the development and distribution of pharmaceuticals of generic products and of brand pharmaceuticals, focused on Urology, women's health and Nephrology/Medical.

Sanofi-Aventis To Purchase Diabel Manufacturing Facility In Frankfurt

Scope of acquisition includes buildings, equipment, machinery and some existing contracts ...

Eli Lilly Announces New Drug Discovery Initiative

Lilly' Phenotypic Drug Discovery Initiative to use indigeneously developed disease-state assays and secure web portal ...

Pfizer' Reveals Results For Four Lung Cancer Trials

Pfizer has announced positive results from four studies highlighting clinical data with targeted treatment approaches in patients with non-small cell lung cancer. The ong ...

Merck Terminates Research Collaboration, License Agreement

Entered the collaboration with Neuromed in March, 2006 ...

Macrogenics, Lilly Reaches Targeted Patient Enrollment In Protege Trial

More than 530 individuals enrolled, across 14 countries ...

Initial Therapy With Merck' JANUMET To Provide Greater Blood Sugar Lowering

Data pooled from 104 weeks of studies showed sustained results for over two years ...

Merck’ Declaration In Response To FDA's Update On Singulair

Singulair, supported by data from controlled clinical trials in more than 20,000 patients ...

Lilly' Phase-II Trial Results For LY2189265 Positive

LY2189265 showed an insulinotropic (stimulating the secretion of insulin) effect. ...

ImClone, Bristol-Myers Squibb Sign Agreement With Merck

For co-development and co-commercialization of Erbitux in Japan ...

Eli Lilly Resubmits Cymbalta Supplemental New Drug Application To FDA

Application is supported by studies in diabetic peripheral neuropathic pain and fibromyalgia ...

Network Sites

Contract Research Clinical Trials Contract Services Drug Delivery Drug Discovery & Development OTC Regulatory Affairs Process and Production IT and Software Laboratory Instrumentation Manufacturing Fine & Specialty Chemicals Medical Devices Business Review Inward Investment Packaging

Mail sent successfully

Tell your friend about this article

Please enter a valid email address

Please enter your name

Please enter the mail body

Your Name: *

Your Email: *

Friend's Email: *

Email Body: *: I thought you would be interested in this article : http://www.pharmaceutical-business-review.com/news/watson_wins_fda_approval_for_levonorgestrel_090624/

Suppliers To This Sector

Browse A-Z

# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

ADAPT Localization

The Translation and Localization Specialists ...

Adis

Independently Evaluated Drug Information ...

Almac

Drug Development Solutions ...

Altiora

To Strive for the Highest ...

Anoto

Providing Unique Technology for Digital Pen and Paper ...

Aptuit

Drug Discovery and Development ...

White Papers

Browse A-Z

# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Related Companies

Sepracor Inc.

Sepracor Inc. (Sepracor) is a research oriented pharmaceutical company that is principa ...

Pfizer Inc.

Pfizer Inc. (Pfizer) is a global research based pharmaceutical company principally focu ...

Sepracor Inc.

Sepracor Inc. (Sepracor) is a research oriented pharmaceutical company that is principa ...

Merck & Co., Inc.

Merck & Co., Inc. (Merck) is a global research-driven pharmaceutical company engaged in ...

Amgen Inc.

Amgen Inc. (Amgen) is a biotechnology company that is focused on the discovery, develo ...

Suppliers Product News

Almac Completes Phase One of Its Expansion Plan to Pharma Services Facilities

New $15m facility will "meet growing business need for its integrated product development and commercial services."

Organisations Throwing Mobile Technology at Problems With Little Consideration of Actual User and Business Needs, Quocirca

Survey reveals detrimental impact on organisational effectiveness and IT expenditure in healthcare and finance across the UK, France, Germany and the US.

Digital Pen and Paper Technology Helps Accelerate Clinical Trials

Digital pen and paper technology captures handwritten clinical data electronically, quickly and securely to save time and cost in drug discovery process.

Aptuit Outlines 2010 Business Priorities at 28th Annual J.P. Morgan Healthcare Conference

Aptuit, Inc., a contract development and manufacturing company, today will provide an update on 2010 business priorities and discuss its integrated service offerings at the 28th Annual J.P. Morgan Healthcare Conference in San Francisco.

Aptuit Publishes Study which Demonstrates the Value of Early Insights into the Characterisation of Drug Compounds

New research on the solid-state characterisation of finasteride clearly outlines a systematic approach to characterising and monitoring active pharmaceutical ingredients

Aptuit Launches Program to Accelerate Early Stage Drug Development

Aptuit INDiGO™ accelerates drug development from pre-clinical candidate selection to regulatory filing on a fixed timeline and price

Free Newsletter Sign-up

Sign up, and we will send you a free Pharmaceutical report on “ Combination Products – Evolution of the Medical Equipment Industry” from GlobalData worth $750